drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Fully human anti-CD20 IgG1κ monoclonal antibody (brand name Kesimpta) administered subcutaneously; binds a membrane-proximal epitope on CD20 on B lymphocytes to induce rapid, sustained depletion of circulating CD20+ B cells via CDC, ADCC, and phagocytosis while sparing stem cells and plasma cells; reduces BCR-driven activity, antigen presentation, proinflammatory cytokine release, and autoantibody contribution to dampen CNS inflammation in RMS.
nci_thesaurus_concept_id
C66952
nci_thesaurus_preferred_term
Ofatumumab
nci_thesaurus_definition
A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.
drug_mesh_term
Ofatumumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Fully human anti-CD20 IgG1κ monoclonal antibody that binds a membrane-proximal epitope on CD20 on B lymphocytes, inducing rapid, sustained depletion of CD20+ B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytosis; spares stem cells and plasma cells, thereby reducing B-cell receptor signaling, antigen presentation, proinflammatory cytokine release, and autoantibody production.
drug_name
Ofatumumab
nct_id_drug_ref
NCT05809986